Childhood medulloblastoma: Current status of biology and treatment

CNS Drugs

Volumn 24, Issue 4, 2010, Pages 285-301

  Klesse, Laura J ^a   Bowers, Daniel C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BETA CATENIN; CARBOPLATIN; CISPLATIN; CYCLOPAMINE; CYCLOPHOSPHAMIDE; ETOPOSIDE; FOLINIC ACID; LOMUSTINE; METHOTREXATE; NOTCH RECEPTOR; OXALIPLATIN; PREDNISONE; PROTEIN PATCHED 1; PROTEIN TYROSINE KINASE; RETINOIC ACID; SONIC HEDGEHOG PROTEIN; TEMOZOLOMIDE; TOPOTECAN; TRASTUZUMAB; VINCRISTINE; WNT1 PROTEIN;

ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN TUMOR; CANCER SURVIVAL; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CEREBROSPINAL FLUID CYTOLOGY; CHILDHOOD; CHROMOSOME 17P; CHROMOSOME LOSS; CLINICAL TRIAL; COGNITIVE DEFECT; DNA REPLICATION; DRUG MEGADOSE; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HORMONE DEFICIENCY; HUMAN; INFERTILITY; LEUKEMIA; LOW DRUG DOSE; MEDULLOBLASTOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUROECTODERM TUMOR; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RNA TRANSCRIPTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MEDULLOBLASTOMA; PROGNOSIS; RISK FACTORS;

EID: 77949599402     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11530140-000000000-00000     Document Type: Review

References (135)

1. CBTRUS. Statistical report: primary brain tumors in the United States 2005-2006 [online]. Hinsdale (IL): Central Brain Tumor Registry of United States 2009. Available from URL: http://www.cbtrus.org [Accessed 2010 Jan 26]
2. Chan AW, Tarbell NJ, Black PM, et al. Adult medullo-blastoma: prognostic factors and patterns of relapse. Neurosurgery 2000 Sep; 47 (3): 623-31; discussion 31-32
3. Halperin EC, Friedman HS. Is there a correlation between duration of presenting symptoms and stage of medullo-blastoma at the time of diagnosis? Cancer 1996 Aug 15; 78 (4): 874-880
4. Coffin CM, Braun JT, Wick MR, et al. A clinicopathologic and immunohistochemical analysis of 53 cases of me-dulloblastoma with emphasis on synaptophysin expression. Mod Pathol 1990 Mar; 3 (2): 164-170
5. Burger PC, Grahmann FC, Bliestle A, et al. Differentiation in the medulloblastoma: a histological and immunohisto-chemical study. Acta Neuropathol 1987; 73 (2): 115-123
6. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (2): 97-109
7. Eberhart CG, Burger PC. Anaplasia and grading in me-dulloblastomas. Brain Pathol 2003 Jul; 13 (3): 376-385
8. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histo-pathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002 Jan 15; 94 (2): 552-560
9. Gajjar A, Hernan R, Kocak M, et al. Clinical, histo-pathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medullo-blastoma. J Clin Oncol 2004 Mar 15; 22 (6): 984-993
10. Packer RJ, Rood BR, MacDonald TJ. Medulloblastoma: present concepts of stratification into risk groups. Pediatr Neurosurg 2003 Jul; 39 (2): 60-67
11. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 1999; 17 (3): 832-845
12. Wiener MD, Boyko OB, Friedman HS, et al. False-positive spinal MR findings for subarachnoid spread of primary CNS tumor in postoperative pediatric patients. AJNR Am J Neuroradiol 1990; 11 (6): 1100-1103
13. Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005 Mar 10; 352 (10): 978-986
14. Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols. Pediatr Blood Cancer 2008 Jun; 50 (6): 1169-1175
15. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medullo-blastoma. J Clin Oncol 2006 Sep 1; 24 (25): 4202-4208
16. Gottardo NG, Gajjar A. Current therapy for medullo-blastoma. Curr Treat Options Neurol 2006; 8 (4): 319-334
17. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006 Oct; 7 (10): 813-820
18. Fouladi M, Gilger E, Kocak M, et al. Intellectual and functional outcome of children 3 years old or younger who have CNS malignancies. J Clin Oncol 2005 Oct 1; 23 (28): 7152-7160
19. Geyer JR, Sposto R, Jennings M, et al. Multiagent chemo-therapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 2005 Oct 20; 23 (30): 7621-7631
20. Geyer JR, Zeltzer PM, Boyett JM, et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 1994 Aug; 12 (8): 1607-1615
21. Duffner PK, Horowitz ME, Krischer JP, et al. The treat-ment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol 1999 Apr; 1 (2): 152-161
22. Duffner PK, Horowitz ME, Krischer JP, et al. Post-operative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993 Jun 17; 328 (24): 1725-1731
23. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of me-dulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 2005; 6: 573-580
24. Grotzer MA, von Hoff K, von Bueren AO, et al. Which clinical and biological tumor markers proved predictive in the prospective multicenter trial HIT'91: implications for investigating childhood medulloblastoma. Klin Padiatr 2007 Nov-Dec; 219 (6): 312-317
25. Ellison DW, Onilude OE, Lindsey JC, et al. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol 2005 Nov 1; 23 (31): 7951-7957
26. Eberhart CG, Kratz J, Wang Y, et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 2004 May; 63 (5): 441-449
27. Segal RA, Goumnerova LC, Kwon YK, et al. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci USA 1994; 91 (26): 12867-12871
28. Korshunov A, Savostikova M, Ozerov S. Immunohisto-chemical markers for prognosis of average-risk pediatric medulloblastomas: the effect of apoptotic index, TrkC, and C-myc expression. J Neurooncol 2002; 58 (3): 271-279
29. Aldosari N, Bigner SH, Burger PC, et al. MYCC and MYCN oncogene amplification in medulloblastoma: a fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 2002 May; 126 (5): 540-544
30. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001 Aug; 7 (8): 2425-2433
31. Hernan R, Fasheh R, Calabrese C, et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res 2003 Jan 1; 63 (1): 140-148
32. Scheurlen WG, Schwabe GC, Joos S, et al. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol 1998 Jul; 16 (7): 2478-2485
33. Haberler C, Slavc I, Czech T, et al. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer 2006; 42 (17): 2996-3003
34. Ellison DW, Clifford SC, Gajjar A, et al. What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 2003; 7 (2): 53-66
35. Fan X, Eberhart CG. Medulloblastoma stem cells. J Clin Oncol 2008 Jun 10; 26 (17): 2821-2827
36. Gilbertson RJ, Gutmann DH. Tumorigenesis in the brain: location, location, location. Cancer Res 2007 Jun 15; 67 (12): 5579-5582
37. Gilbertson RJ. Medulloblastoma: signalling a change in treatment. Lancet Oncol 2004 Apr; 5 (4): 209-218
38. Gilbertson RJ, Gajjar A. Molecular biology of medullo-blastoma: will it ever make a difference to clinical management? J Neurooncol 2005 Dec; 75 (3): 273-278
39. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3 (32): 1-16
40. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996 Jun 14; 85 (6): 841-851
41. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996 Jun 14; 272 (5268): 1668-1671
42. Wechsler-Reya RJ, Scott MP. Control of neuronal pre-cursor proliferation in the cerebellum by Sonic hedgehog. Neuron 1999 Jan; 22 (1): 103-114
43. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu Rev Neurosci 2001; 24: 385-428
44. Lee Y, Miller HL, Jensen P, et al. A molecular fingerprint for medulloblastoma. Cancer Res 2003 Sep 1; 63 (17): 5428-5437
45. Pietsch T, Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res 1997 Jun 1; 57 (11): 2085-2088
46. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 2000 Jan; 27 (1): 44-51
47. Zurawel RH, Allen C, Wechsler-Reya R, et al. Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000 May; 28 (1): 77-81
48. Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res 2005 Jul 1; 11 (13): 4733-4740
49. Di Marcotullio L, Ferretti E, De Smaele E, et al. REN(KCTD11) is a suppressor of hedgehog signalling and is deleted in human medulloblastoma. Proc Natl Acad Sci USA 2004 Jul 20; 101 (29): 10833-10838
50. De Smaele E, Di Marcotullio L, Ferretti E, et al. Chromo-some 17p deletion in human medulloblastoma: a missing checkpoint in the Hedgehog pathway. Cell Cycle 2004 Oct; 3 (10): 1263-1266
51. Fiuza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol 2007 Sep; 194 (3): 459-474
52. Shih Ie M, Wang TL. Notch signalling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 2007 Mar 1; 67 (5): 1879-1882
53. Lissemore JL, Starmer WT. Phylogenetic analysis of ver-tebrate and invertebrate Delta/Serrate/LAG-2 (DSL) proteins. Mol Phylogenet Evol 1999 Mar; 11 (2): 308-319
54. Singh SK, Clarke ID, Hide T, et al. Cancer stem cells in nervous system tumors. Oncogene 2004 Sep 20; 23 (43): 7267-7273
55. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003 Sep 15; 63 (18): 5821-5828
56. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004 Nov 18; 432 (7015): 396-401
57. Fan X, Matsui W, Khaki L, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006 Aug 1;66 (15): 7445-7452
58. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 2000 Apr; 59 (4): 333-337
59. Clifford SC, Lusher ME, Lindsey JC, et al. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 2006 Nov; 5 (22): 2666-2670
60. Salaroli R, Di Tomaso T, Ronchi A, et al. Radiobiologic response of medulloblastoma cell lines: involvement of beta-catenin? J Neurooncol 2008; 90 (3): 243-251
61. Kratz JE, Stearns D, Huso DL, et al. Expression of stabi-lized beta-catenin in differentiated neurons of transgenic mice does not result in tumor formation. BMC Cancer 2002 Dec 2; 233: 1-9
62. Gilbertson RJ, Perry RH, Kelly PJ, et al. Prognostic significance of HER2 and HER4 coexpressionin childhood medulloblastoma. Cancer Res 1997 Aug 1; 57 (15): 3272-3280
63. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medullo-blastoma. Br J Cancer 2001 Sep 1; 85 (5): 705-712
64. Slongo ML, Molena B, Brunati AM, et al. Functional VEGF and VEGF receptors are expressed in human me-dulloblastomas. Neuro Oncol 2007 Oct; 9 (4): 384-392
65. Patti R, Reddy CD, Geoerger B, et al. Autocrine secreted insulin-like growth factor-I stimulates MAP kinase-dependent mitogenic effects in human primitive neuro-ectodermal tumor/medulloblastoma. Int J Oncol 2000 Mar; 16 (3): 577-584
66. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000 Sep 15; 275 (37): 28341-28344
67. Li Y, Guessous F, Johnson EB, et al. Functional and mol-ecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma. Lab Invest 2008 Feb; 88 (2): 98-111
68. Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005 Oct 15; 65 (20): 9355-9362
69. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 2001 Jan 15; 61 (2): 513-516
70. Hallahan AR, Pritchard JI, Hansen S, et al. The SmoA1 mouse model reveals that notch signalling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 2004 Nov 1; 64 (21): 7794-7800
71. Goodrich LV, Milenkovic L, Higgins KM, et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997 Aug 22; 277 (5329): 1109-1113
72. Hatton BA, Villavicencio EH, Tsuchiya KD, et al. The Smo/Smo model: hedgehog-induced medulloblastoma with 90% incidence and leptomeningeal spread. Cancer Res 2008 Mar 15; 68 (6): 1768-1776
73. Romer J, Curran T. Targeting medulloblastoma: small-molecule inhibitors of the Sonic hedgehog pathway as potential cancer therapeutics. Cancer Res 2005 Jun 15; 65 (12): 4975-4978
74. Romer JT, Kimura H, Magdaleno S, et al. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 2004 Sep; 6 (3): 229-240
75. Matthay KK, Villablanca JG, Seeger RC, et al., on behalf of the Children's Cancer Group. Treatment of high-risk neuro-blastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999 Oct 14; 341 (16): 1165-1173
76. Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008 Mar 1; 111 (5): 2505-2515
77. Chang Q, Chen Z, You J, et al. All-trans-retinoic acid in-duces cell growth arrest in a human medulloblastoma cell line. J Neurooncol 2007 Sep; 84 (3): 263-267
78. Hallahan AR, Pritchard JI, Chandraratna RA, et al. BMP-2 mediates retinoid-induced apoptosis in medullo-blastoma cells through a paracrine effect. Nat Med 2003 Aug; 9 (8): 1033-1038
79. Damodar Reddy C, Guttapalli A, Adamson PC, et al. Anticancer effects of fenretinide in human medullo-blastoma. Cancer Lett 2006 Jan 18; 231 (2): 262-269
80. Spiller SE, Ditzler SH, Pullar BJ, et al. Response of pre-clinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 2008 Apr; 87 (2): 133-141
81. Peretto I, La Porta E. Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr Top Med Chem 2008; 8 (1): 38-46
82. Evin G. Gamma-secretase modulators: hopes and setbacks for the future of Alzheimer's treatment. Expert Rev Neurother 2008 Nov; 8 (11): 1611-1613
83. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002 Aug 30; 297 (5586): 1559-1561
84. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361 (12): 1173-1178
85. Emanuel SL, Hughes TV, Adams M, et al. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Mol Pharmacol 2008 Feb; 73 (2): 338-348
86. Easwaran V, Pishvaian M, Salimuddin, et al. Cross-regulation of beta-catenin-LEF/TCF and retinoid signalling pathways. Curr Biol 1999 Dec 2; 9 (23): 1415-1418
87. Mulhern RK, Merchant TE, Gajjar A, et al. Late neuro-cognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol 2004; 5 (7): 399-408
88. Duffner P. Long-term effects of radiation therapy on cog-nitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10 (6): 293-310
89. Evans AE, Jenkin RD, Sposto R, et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vin-cristine, and prednisone. J Neurosurg 1990; 72 (4): 572-582
90. Tait DM, Thornton-Jones H, Bloom HJ, et al. Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). Eur J Cancer 1990; 26 (4): 464-469
91. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 2003 Apr 15; 21 (8): 1581-1591
92. Packer RJ, Goldwein JW, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study. J Clin Oncol 1999; 17: 2127-2136
93. Kretschmar CS, Tarbell NJ, Kupsky W, et al. Pre-irradiation chemotherapy for infants and children with medullo-blastoma: a preliminary report. J Neurosurg 1989; 71 (6): 820-825
94. Mosijczuk AD, Nigro MA, Thomas PRM, et al. Preradia-tion chemotherapy in advanced medulloblastoma: a Pediatric Oncology Group pilot study. Cancer 1993; 72 (9): 2755-2762
95. Kortmann R-D, Kuhl J, Timmermann B, et al. Post-operative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medullo-blastoma in childhood: results of the German prospective randomized trial HIT'91. Int J Radiat Oncol Biol Phys 2000; 46 (2): 269-279
96. Lampkin BC, Mauer AM, McBride BH. Response to medulloblastoma to vincristine sulfate: a case report. Pediatrics 1967 May 1; 39 (5): 761-763
97. Jackson Jr D, Sethi V, Spurr C, et al. Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 1981; 41: 1466-1468
98. Kellie SJ, Barbaric D, Koopmans P, et al. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing. Cancer 2002; 94 (6): 1815-1820
99. Packer RJ. Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 1990; 28: 823-828
100. Allen JC, Helson L. High-dose cyclophosphamide chemo-therapy for recurrent CNS tumors in children. J Neuro-surg 1981; 55: 749-756
101. Moghrabi A, Fuchs H, Brown M, et al. Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. Med Pediatr Oncol 1995; 25 (3): 190-196
102. Nicholson HS, Kretschmar CS, Krailo M, et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors. Cancer 2007; 110 (7): 1542-1550
103. Packer RJ, Sutton LN, Elterman RD, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neuro-surg 1994; 81: 690-698
104. Allen JC, Walker R, Luks E, et al. Carboplatin and re-current childhood brain tumors. J Clin Oncol 1987 Mar 1; 5 (3): 459-463
105. Gaynon PS, Ettinger LJ, Baum ES, et al. Carboplatin in childhood brain tumors: a Children's Cancer Study Group Phase II trial. Cancer 1990; 66 (12): 2465-2469
106. Mastrangelo R, Lasorella A, Riccardi R, et al. Carboplatin in childhood medulloblastoma/PNET: feasibility of an in vivo sensitivity test in an "up-front" study. Med Ped Oncol 1995; 24 (3): 188-196
107. Bergman I, Jakacki RI, Heller G, et al. Treatment of stan-dard risk medulloblastoma with craniospinal irradiation, carboplatin, and vincristine. Med Pediatr Oncol 1997 Dec; 29 (6): 563-567
108. Misset JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 2000; 35 (2): 75-93
109. Fouladi M, Blaney SM, Poussaint TY, et al. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroecto-dermal tumors, and atypical teratoid rhabdoid tumors. Cancer 2006; 107 (9): 2291-2297
110. Fossati-Bellani F, Tesoro-Tess JD, Ballerini E. Medullo-blastoma (MBL): evaluation of the effectiveness of pre-radiation (RT) chemotherapy (CT) [abstract]. Med Ped Oncol 1990; 18: 361
111. Allen JC, Walker R, Rosen G. Preradiation high-dose in-travenous methotrexate with leucovorin rescue for untreated primary childhood brain tumors. J Clin Oncol 1988 Apr 1; 6 (4): 649-653
112. Lashford L, Campbell R, Gattamaneni H, et al. An inten-sive multiagent chemotherapy regimen for brain tumours occurring in very young children. Arch Dis Child 1996 Mar 1; 74 (3): 219-223
113. Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 2004 Dec 15; 22 (24): 4881-4887
114. Mason W, Grovas A, Halpern S, et al. Intensive chemo-therapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998 Jan 1; 16 (1): 210-221
115. Kadota RP, Stewart CF, Horn M, et al. Topotecan for the treatment of recurrent or progressive central nervous system tumors: a Pediatric Oncology Group phase II study. J Neurooncol 1999; 43 (1): 43-47
116. Blaney SM, Phillips PC, Packer RJ, et al. Phase II evalua-tion of topotecan for pediatric central nervous system tumors. Cancer 1996; 78 (3): 527-531
117. Strother D, Ashley D, Kellie SJ, et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medullo-blastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 2001 May 15; 19 (10): 2696-2704
118. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004 Aug 15; 22 (16): 3357-3365
119. Kovnar EH, Kellie SJ, Horowitz ME, et al. Preirradiation cisplatin and etoposide in the treatment of high-risk me-dulloblastoma and other malignant embryonal tumors of the central nervous system: a phase II study. J Clin Oncol 1990 Feb 1; 8 (2): 330-336
120. Ashley DM, Meier L, Kerby T, et al. Response of recurrent medulloblastoma to low-dose oral etoposide. J Clin Oncol 1996; 14 (6): 1922-1927
121. Moghrabi A, Hershon L, Rousseau P, et al. A phase I/II feasibility study of oral etoposide given concurrently with radiotherapy followed with dose-intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma COG P9631 [abstract]. Neuro-oncology 2008; 10 (3): 476.
122. 13th Annual ISPNO Meeting; 29 Jun-2 Jul 2008; Chicago (IL)
123. Dupuis-Girod S, Hartmann O, Benhamou E, et al. Will high-dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neuro-Oncol 1996; 27: 87-98
124. Mahoney Jr DH, Strother D, Camitta B, et al. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot Pediatric Oncology Group study. J Clin Oncol 1996; 14: 382-388
125. Graham ML, Herndon 2nd JE, Casey JR, et al. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 1997; 15 (5): 1814-1823
126. Guruangan S, Dunkel IJ, Goldman S, et al. Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 1998; 16: 2486-2493
127. Dunkel IJ, Boyett JM, Yates A, et al. High-dose carbo-platin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998; 16 (1): 222-228
128. Grill J, Renaux VK, Bulteau C, et al. Long-term in-tellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999; 45 (1): 137-145
129. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol 2001; 19: 480-487
130. Paulino AC. Hypothyroidism in children with medullo-blastoma: a comparison of 3600 and 2340 cGy cranio-spinal radiotherapy. Int J Radiat Oncol Biol Phys 2002; 53 (3): 543-547
131. Gurney JG, Ness KK, Stovall M, et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2003 Oct 1; 88 (10): 4731-4739
132. Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002; 52 (3): 599-605
133. Fukunaga-Johnson N, Sandler HM, Marsh R, et al. The use of 3D conformal radiotherapy (3D CRT) to spare the cochlea in patients with medulloblastoma. Int J Radiat Oncol Biol Phys 1998; 41 (1): 77-82
134. Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23 (34): 8588-8596
135. Lamont JM, McManamy CS, Pearson AD, et al. Com-bined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 2004 Aug 15; 10 (16): 5482-5493